Elvitegravir

EVG is only available as a component of an STR tablet that also contains COBI, FTC, and either TDF or TAF (Stribild, Genvoya).

ARV U.S. Brand Name

Vitekta

ARV Abbreviation(s)

EVG

ARV Class

Integrase inhibitors

First U.S. Approval

August 27, 2012

U.S. Manufacturer

Gilead Sciences

Generic Available?

Adult dosing

FDCs

Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide

Elvitegravir / Cobicistat / Tenofovir DF / Emtricitabine

Displaying 1 - 100 of 157

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Elvitegravir Erythromycin 280	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination					Use alternative agents
Elvitegravir Nefazodone 279	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of nefazodone adverse effects				Use alternative agents
Elvitegravir Dexamethasone 278	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential loss of antiviral efficacy				Monitor viral load if extended dexamethasone use. Consider alternative corticosteroid for long-term use.
Elvitegravir Eluxadoline 277	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of eluxadoline adverse effects				Monitor response and titrate according to efficacy and adverse effects.
Elvitegravir Itraconazole 276	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased adverse effects from both elvitegravir and itraconazole				Monitor itraconazole concentrations. If coadministering itraconazole dose should not exceed 200 mg daily unless guided by concentrations.
Elvitegravir Tramadol 275	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased sedation				Initiate tramadol at lowest dose. If initiating elvitegravir / cobicistat, tramadol may require a dose reduction - monitor for efficacy and adverse effects to titrate.
Elvitegravir Fentanyl 274	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of sedation and respiratory depression				If coadministering, titrate carefully and monitor for sedation and respiratory depression
Elvitegravir Posaconazole 273	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination					If coadministering, monitor posaconazole concentrations.
Elvitegravir Ketoconazole 272	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased adverse effects from both elvitegravir and ketoconazole				If coadministering, ketoconazole dose should not exceed 200 mg daily.
Elvitegravir CsA 271	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased cyclosporine toxicity	Not reported			If coadministering, initiate lower dose of immunosuppressant, therapeutic drug monitoring is recommended, assess toxicity, consult with specialist, and adjust dose as necessary
Elvitegravir Tacrolimus 270	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased tacrolimus adverse effects (increased immunosuppression)				If coadministering, initiate lower dose of immunosuppressant, therapeutic drug monitoring is recommended, assess toxicity, consult with specialist, and adjust dose as necessary
Elvitegravir Sirolimus 269	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased sirolimus adverse effects (increased immunosuppression)				If coadministering, initiate lower dose of immunosuppressant, therapeutic drug monitoring is recommended, assess toxicity, consult with specialist, and adjust dose as necessary
Elvitegravir Propafenone 268	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of propafenone adverse effects				If coadministering use with caution and monitor for propafenone toxicity. Consider therapeutic drug monitoring and ECG
Elvitegravir Mexiletine 267	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of mexiletine adverse effects				If coadministering use with caution and monitor for mexiletine toxicity. Consider therapeutic drug monitoring and ECG
Elvitegravir Lidocaine 266	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of lidocaine adverse effects				If coadministering use with caution and monitor for lidocaine toxicity. Consider therapeutic drug monitoring and ECG if used systemically.
Elvitegravir Flecainide 265	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of flecainide adverse effects (eg, cardiac arrhythmias)				If coadministering use with caution and monitor for flecainide toxicity. Consider therapeutic drug monitoring and ECG
Elvitegravir Disopyramide 264	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of disopyramide adverse effects				If coadministering use with caution and monitor for disopyramide toxicity. Consider therapeutic drug monitoring and ECG
Elvitegravir Amiodarone 263	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased amiodarone effects (eg, hypotension, bradycardia, cardiac arrhythmias)				If coadministering use with caution and monitor for amiodarone toxicity. Consider therapeutic drug monitoring and ECG.
Elvitegravir Verapamil 262	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of verapamil adverse effects				If coadministering use with caution and monitor ECG
Elvitegravir Nifedipine 261	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of nifedipine adverse effects				If coadministering use with caution and monitor ECG
Elvitegravir Nicardipine 260	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of nicardipine adverse effects				If coadministering use with caution and monitor ECG
Elvitegravir Felodipine 259	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of felodipine adverse effects				If coadministering use with caution and monitor ECG
Elvitegravir Diltiazem 258	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of diltiazem adverse effects				If coadministering use with caution and monitor ECG
Elvitegravir Amlodipine 257	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of amlodopine adverse effects				If coadministering use with caution and monitor ECG
Elvitegravir Lofexidine 256	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of lofexidine adverse effects (e.g. orthostasis and bradycardia)				If coadministering use with caution and monitor blood pressure, heart rate, and dizziness.
Elvitegravir Fluoxetine 255	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of fluoxetine adverse effects				If coadministering start with lowest fluoxetine dose. Monitor response and titrate dose according to efficacy and adverse effects
Elvitegravir Ziprasidone 254	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of ziprasidone adverse effects				If coadministering start with low dose and titrate accordingly. Monitor for side effects.
Elvitegravir Zolpidem 253	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of sedative-hypnotic adverse effects				If coadministering start with low dose and titrate accordingly. Monitor for side effects.
Elvitegravir Flurazepam 252	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of sedative-hypnotic adverse effects				If coadministering start with low dose and titrate accordingly. Monitor for side effects.
Elvitegravir Estazolam 251	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of sedative-hypnotic adverse effects				If coadministering start with low dose and titrate accordingly. Monitor for side effects.
Elvitegravir Diazepam 250	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of sedative-hypnotic adverse effects				If coadministering start with low dose and titrate accordingly. Monitor for side effects.
Elvitegravir Clorazepate 249	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of sedative-hypnotic adverse effects				If coadministering start with low dose and titrate accordingly. Monitor for side effects.
Elvitegravir Isavuconazole 248	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination					If coadministering monitor isavuconazole concentrations and assess virologic response.
Elvitegravir Warfarin 247	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential over or under anticoagulation				If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
Elvitegravir Dronedarone 246	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of dronedarone adverse effects				If coadministering monitor for dronedarone toxicity. Consider therapeutic drug monitoring and ECG.
Elvitegravir Prednisone 245	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of adrenal insufficiency and Cushing's syndrome, but PK / PD less affected by strong CYP3A4 inhibitors				If coadministering monitor for adrenal insufficiency and Cushing's syndrome
Elvitegravir Everolimus 244	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased everolimus effects (e.g. excessive immunosuppression)				If coadministering monitor everolimus levels and adjust dose as indicated
Elvitegravir Citalopram 243	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased SSRI adverse effects				If coadministering initiate therapy with lowest citalopram dose. Monitor citalopram response and titrate dose according to efficacy and adverse effects.
Elvitegravir Escitalopram 242	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential increase in SSRI adverse effects				If coadministering initiate escitalopram therapy with lowest dose. Monitor escitalopram response and titrate according to efficacy and adverse effects
Elvitegravir Dronabinol 241	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of dronabinol adverse effects (e.g. sedation)				If coadministering initiate dronabinol at lowest dose. Monitor response and titrate according to efficacy and adverse effects.
Elvitegravir Prednisolone 240	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of adrenal insufficiency and Cushing's syndrome, but PK / PD less affected by strong CYP3A4 inhibitors				If coadministering for systemic use, monitor for adrenal insufficiency and Cushing's syndrome. Do not coadminister if prednisolone needed for local injections.
Elvitegravir Voriconazole 239	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination					If coadministering assess risk and benefit. Consider monitoring voriconaozle concentrations.
Elvitegravir Ciclesonide 238	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				If coadministering assess risk and benefit
Elvitegravir Dutasteride 237	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of dutasteride adverse effects				If coadministering adjust dutasteride dose based on clinical effects and endogenous hormone concentrations.
Elvitegravir Dabigatran 236	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of bleeding				Dosing depends on indication and renal function. For DVT and PE, avoid co-administration if CrCL < 50 mL / min. For stroke and embolism prevention in persons with atrial fibrillation, do not coadminister in severe renal insufficiency (CrCL< 30mL / min) and consider dose reduction to 75 mg twice daily if CrCL between 30 - 50mL / min
Elvitegravir Fluvoxamine 235	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decreased elvitegravir effects				Consider using alternative antidepressant
Elvitegravir Quetiapine 234	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of quetiapine adverse effects				Consider alternative ARV therapy. For patients currently on elvitegravir / cobicistat: initiate quetiapine at lowest dose. Titrate accordingly and monitor for adverse effects. If patient already on quetiapine and requiring new elvitegravir / cobicistat: reduce queitapine to 1 / 6 of original dose before coadministering. Monitor efficacy and adverse effects.
Elvitegravir Timolol 233	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of timolol adverse effects				Consider alternative agents. If coadministering initiate beta-blocker at low dose and titrate to clinical effect while monitoring for adverse effects.
Elvitegravir Metoprolol 232	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of metoprolol adverse effects				Consider alternative agents. If coadministering initiate beta-blocker at low dose and titrate to clinical effect while monitoring for adverse effects.
Elvitegravir Betrixaban 231	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of bleeding				Administer single dose of betrixaban 80 mg, followed by betrixaban 40 mg once daily
Elvitegravir Testosterone 230	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of testosterone adverse effects				Adjust testosterone dose based on clinical effects and endogenous hormone concentrations.
Elvitegravir Oxcarbazepine 229	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decrease in antiretroviral efficacy				Use alternative agents
Elvitegravir Budesonide 228	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				Use alternative agents
Elvitegravir Tamsulosin 227	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased tamulosin adverse effects				Use alternate agents. If coadministering, use with caution and monitor for tamulosin related adverse effects
Elvitegravir Quinidine 226	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of quinidine adverse effects (e.g. cardiac arrhythmias)				If coadministering use with caution and monitor for quinidine toxicity. Consider therapeutic drug monitoring and ECG
Elvitegravir Betamethasone 225	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				Do not coadminister if betamethasone used for local injection.
Elvitegravir Apixaban 224	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding				Consider avoiding combination and using alternative anticoagulant. If coadministering, reduce apixaban dose by 50% in patients who require 5-10 mg twice daily. Do not coadminister in persons who require apixaban 2.5mg twice daily.
Elvitegravir Rivaroxaban 223	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding				Avoid combination and use alternative anticoagulant
Elvitegravir Ethinyl estradiol / Drospirenone 222	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased drospirenone effects (hyperkalemia); Potential decreased ethinyl estradiol effects				Additional or alternative contraception should be considered. If using, monitor potassium.
Elvitegravir LNG 221	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential increase in levonorgestrel adverse effects				Additional or alternative contraception should be considered.
Elvitegravir RPT 220	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Potential decrease in antiretroviral efficacy				Use alternative agents
Elvitegravir St. John's Wort (Hypericum perforatum) 219	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents.
Elvitegravir Eslicarbazepine 218	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents.
Elvitegravir Phenytoin 217	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents.
Elvitegravir Phenobarbital 216	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Potential decrease in antiretroviral efficacy				Contraindicated. Use alternative agents.
Elvitegravir RIF 215	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir	Expected significant decreased in elvitegravir, cobicistat. Potential decreased antiretroviral efficacy				Contraindicated. Use alternative agents.
Elvitegravir Clopidogrel 214	Red: Avoid combination	Do not coadminister: Potential for reduced levels of clopidogrel	Potential reduction of antiplatelet activity				Use alternative agents
Elvitegravir Vorapaxar 213	Red: Avoid combination	Do not coadminister: Potential for increased levels of vorapaxar	Potential for increased risk of bleeding				Avoid combination and use alternative antiplatelet agent
Elvitegravir Ticagrelor 212	Red: Avoid combination	Do not coadminister: Potential for increased levels of ticagrelor	Potential for increased risk of bleeding				Avoid combination and use alternative antiplatelet agent.
Elvitegravir Suvorexant 211	Red: Avoid combination	Do not coadminister: Potential for increased levels of suvorexant	Potential for increased suvorexant adverse effects				Use alternative agents
Elvitegravir Salmeterol 210	Red: Avoid combination	Do not coadminister: Potential for increased levels of salmeterol	Increased risk of cardiovascular adverse events (e.g. QT prolongation, palpitations, sinus tachycardia)				Use alternative agents
Elvitegravir Ranolazine 209	Red: Avoid combination	Do not coadminister: Potential for increased levels of ranolazine	Potential for increased risk of ranolazine adverse effects				Contraindicated. Use alternative agents.
Elvitegravir Ivabradine 208	Red: Avoid combination	Do not coadminister: Potential for increased levels of ivabradine	Potential for increased risk of ivabradine adverse effects				Contraindicated. Use alternative agents.
Elvitegravir Flibanserin 207	Red: Avoid combination	Do not coadminister: Potential for increased levels of flibanserin	Potential for increased risk of flibanserin adverse effects				Use alternative agents
Elvitegravir Eplerenone 206	Red: Avoid combination	Do not coadminister: Potential for increased levels of eplerenone	Potential for increased risk of eplerenone adverse effects				Contraindicated. Use alternative agents.
Elvitegravir Dofetilide 205	Red: Avoid combination	Do not coadminister: Potential for increased levels of dofetilide	Potential for increased risk of dofetilide adverse effects				Use alternative agents
Elvitegravir Lumateperone 204	Red: Avoid combination	Do not coadminister: potential toxicity	Potential for increased risk of lumateperone adverse effects				Use alternative agents
Elvitegravir Lurasidone 203	Red: Avoid combination	Do not coadminister: potential toxicity	Potential serious or life-threatening reactions				Contraindicated. Use alternative agents.
Elvitegravir Triazolam 202	Red: Avoid combination	Do not coadminister: Potential for increased levels of triazolam	Potential for increased triazolam effects (e.g. prolonged sedation, altered mental status, respiratory depression)				Contraindicated. Use alternative agents.
Elvitegravir Triamcinolone 201	Red: Avoid combination	Do not coadminister: Potential for increased levels of triamcinolone	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				Do not coadminister if triamcinolone is used for local injection.
Elvitegravir Simvastatin 200	Red: Avoid combination	Do not coadminister: Potential for increased levels of simvastatin	Potential for increased simvastatin effects (e.g. myopathy, rhabdomyolysis)				Contraindicated. Use alternative agents.
Elvitegravir Simeprevir 199	Red: Avoid combination	Do not coadminister: Potential for increased levels of simeprevir	Potential for increased simeprevir toxicity				Use alternative agents
Elvitegravir Silodosin 198	Red: Avoid combination	Do not coadminister: Potential for increased levels of silodosin	Potential for increased silodosin adverse effects				Contraindicated. Use alternative agents.
Elvitegravir Pimozide 197	Red: Avoid combination	Do not coadminister: Potential for increased levels of pimozide	Potential serious or life-threatening reactions such as cardiac arrhythmia.				Contraindicated. Use alternative agents.
Elvitegravir Mometasone 196	Red: Avoid combination	Do not coadminister: Potential for increased levels of mometasone	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				Use alternative agents
Elvitegravir Midazolam 195	Red: Avoid combination	Do not coadminister: Potential for increased levels of midazolam	Potential for increased midazolam effects (e.g. prolonged sedation, altered mental status, respiratory depression)				Co-administration of oral midazolam is contraindicated. Parenteral midazolam can be used with caution when given as a single dose in a closely monitored situation for procedural sedation.
Elvitegravir Alprazolam 194	Red: Avoid combination	Do not coadminister: Potential for increased levels of midazolam	Potential for increased alprazolam effects (e.g. sedation, altered mental status, respiratory depression)				Coadministration of EVG with oral midazolam is contraindicated. Parenteral midazolam can be used with caution when given as a single dose in a closely monitored situation for procedural sedation.
Elvitegravir Methylprednisolone 193	Red: Avoid combination	Do not coadminister: Potential for increased levels of methylprednisolone	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				Do not coadminister if methylprednisolone being used for local injection.
Elvitegravir Methylergonovine 192	Red: Avoid combination	Do not coadminister: Potential for increased levels of methylergonovine	Potential for increased ergot effects (e.g. ergot toxicity, peripheral vasospasm, ischemia)				Contraindicated. Use alternative agents.
Elvitegravir HMG-CoA Reductase Inhibitors 191	Red: Avoid combination	Do not coadminister: Potential for increased levels of lovastatin	Potential for increased lovastatin effects (e.g. myopathy, rhabdomyolysis)				Contraindicated. Use alternative agents.
Elvitegravir Fluticasone 190	Red: Avoid combination	Do not coadminister: Potential for increased levels of fluticasone	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				Use alternative agents
Elvitegravir Ergotamine 189	Red: Avoid combination	Do not coadminister: Potential for increased levels of ergotamine	Potential for increased ergot effects (e.g. ergot toxicity, peripheral vasospasm, ischemia)				Contraindicated. Use alternative agents.
Elvitegravir Dihydroergotamine 188	Red: Avoid combination	Do not coadminister: Potential for increased levels of dihydroergotamine	Potential for increased ergot effects (e.g. ergot toxicity, peripheral vasospasm, ischemia)				Contraindicated. Use alternative agents.
Elvitegravir EBR/GZR 187	Red: Avoid combination	Do not coadminister: Potential for increased levels of antivirals	Potential for increased AUC of HCV agents	No significant change		Elbasvir Cmax increased 91%, AUC increased 118%; Grazoprevir Cmax increased 359%, AUC increased436%	Use alternative agents
Elvitegravir Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 186	Red: Avoid combination	Do not coadminister: Potential for increased levels of antivirals	Potential for increased AUC of HCV agents				Use alternative agents
Elvitegravir Alfuzosin 185	Red: Avoid combination	Do not coadminister: Potential for increased levels of alfuzosin	Potential for increased alfuzosin adverse effects (e.g. hypotension)				Contraindicated. Use alternative agents.
Elvitegravir Lomitapide 184	Red: Avoid combination	Do not coadminister: Potential for increased level of lomitapide	Potential for increased risk of elevated transaminases				Contraindicated. Use alternative agents.
Elvitegravir Avanafil 183	Red: Avoid combination	Do not coadminister: Potential for increased level of avanafil	Potential for increased risk avanafil adverse effects				Contraindicated. Use alternative agents.
Elvitegravir Dapagliflozin / Saxagliptin 182	Red: Avoid combination	Do not coadminister: Increased levels of saxagliptin	Potential for increased saxagliptin adverse effects	Not reported	saxagliptin 5 mg	Not reported	Use alternative agents
Elvitegravir G/P 181	Green: Administer standard doses	Administer standard doses	Potential increase in GLEC / PIB toxicity	AUC increased 47%		Glecaprevir AUC increased 3 fold; PIB AUC increased 57%

Subscribe to Elvitegravir